Addex Therapeutics Ltd (SWX:ADXN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
0.0650
+0.0046 (7.62%)
Sep 30, 2025, 5:31 PM CET
7.62%
Market Cap5.94M
Revenue (ttm)167.29K
Net Income (ttm)-6.05M
Shares Out98.35M
EPS (ttm)-0.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume903,988
Average Volume1,133,622
Open0.0660
Previous Close0.0604
Day's Range0.0608 - 0.0680
52-Week Range0.0472 - 0.1095
Beta1.77
RSI58.34
Earnings DateSep 1, 2025

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 2
Stock Exchange SIX Swiss Exchange
Ticker Symbol ADXN
Full Company Profile

Financial Performance

Financial Statements

News

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 In...

19 hours ago - GlobeNewsWire

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulat...

4 days ago - GlobeNewsWire

Addex Appoints Bank of New York Mellon as Depositary Bank

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portf...

7 days ago - GlobeNewsWire

Why Adobe Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket

Shares of Adobe Inc. (NASDAQ: ADBE) rose sharply in pre-market trading after the company posted better-than-expected third-quarter results and raised its fiscal 2025 outlook after Thursday's closing ...

18 days ago - Benzinga

Earnings Scheduled For September 1, 2025

Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ: ADXN) is expected to report ... Full story available on Benzinga.com

4 weeks ago - Benzinga

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a...

3 months ago - GlobeNewsWire

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel s...

3 months ago - GlobeNewsWire

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulati...

3 months ago - GlobeNewsWire

Earnings Scheduled For June 19, 2025

Companies Reporting Before The Bell • 111 (NASDAQ: YI) is likely to report earnings for its first quarter. • Addex Therapeutics (NASDAQ: Full story available on Benzinga.com

3 months ago - Benzinga

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, A...

3 months ago - GlobeNewsWire

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators f...

3 months ago - GlobeNewsWire

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a port...

4 months ago - GlobeNewsWire

Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric mod...

4 months ago - GlobeNewsWire

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of no...

5 months ago - GlobeNewsWire

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...

5 months ago - GlobeNewsWire

Addex Therapeutics reports FY results

5 months ago - Seeking Alpha

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for devel...

5 months ago - GlobeNewsWire

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...

5 months ago - GlobeNewsWire

Addex to Present at the 2025 Swiss Equities Baader Conference

Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators...

9 months ago - GlobeNewsWire

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Adjustments

11 months ago - GuruFocus

Q3 2024 Addex Therapeutics Ltd Earnings Call Transcript

Q3 2024 Addex Therapeutics Ltd Earnings Call Transcript

11 months ago - GuruFocus

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

11 months ago - Seeking Alpha